Table 1 The clinical characteristics of the patients at the time when they filled in the questionnaire at the paediatric site and, later, at their first adult clinic visit
From: Transition readiness among finnish adolescents with juvenile idiopathic arthritis
Questionnaire filled in at paediatric site N = 83 | First adult clinic visit N = 77 | |
|---|---|---|
Female, n (%) | 59 (71) | 53 (69) |
Age at onset, years, mean (SD) | 8.9 (5.2) | |
Age at visit, years, mean (SD) | 14.5 (0.9) | 17.1 (1.5) |
JIA category* n (%) | ||
Polyarthritis, RF+ | 6 (7) | 6 (8) |
Polyarthritis, RF- | 26 (31) | 26 (34) |
Juvenile psoriatic | 5 (6) | 3 (4) |
Enthesitis-related | 5 (6) | 5 (6) |
Undifferentiated | 2 (2) | 2 (3) |
Persistent oligoarthritis | 23 (28) | 22 (29) |
Extended oligoarthritis | 16 (19) | 13 (29) |
Remission**, n (%) | 61 (73) | 54 (71) |
Uveitis, n (%) | 23 (28) | 20 (26) |
Physician’s global VAS 0-100, mean (SD) | 4.3 (8.8) | 4.8 (12.0) |
ESR, mean (SD) | 7.3 (7.6) | 7.6 (6.9) |
Active joints, mean (SD) | 0.5 (1.1) | 0.4 (1.0) |
Patient’s pain VAS 0-100, mean (SD) | 17.3 (22.2) | |
Patient’s global VAS 0-100, mean (SD) | 12.6 (19.6) | |
DAS28, mean (SD) | 1.57 (0.79) | |
Systemic medication, n (%) | 72 (87) | 63 (82) |
Synthetic DMARDs | 68 (82) | 54 (70) |
Biologic DMARDs | 31 (37) | 33 (43) |
Systemic steroids | 19 (23) | 11 (14) |
Smoking, n (%) | 3 (12) | |
Non-restricted social participation, n (%) | 75 (97) | |